Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure Director David D. Meek reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025, at a weighted average price of $14.45 per share (range: $14.40-$14.50). The transaction was executed to cover estimated withholding taxes following the vesting of restricted share units, in accordance with automatic sale instructions in the Restricted Share Unit Agreement.
Following the reported transaction, Meek continues to directly own 34,190 ordinary shares of uniQure. The sale was conducted through automatic sale instructions and was not a discretionary trade by the reporting person.
- Transaction Type: Non-discretionary sale (tax withholding)
- Transaction Code: S
- Ownership Type: Direct
- Role: Director
uniQure N.V. Chief Legal Officer Jeannette Potts reported a non-discretionary sale of 4,670 ordinary shares on June 16, 2025, at a weighted average price of $15.14 per share (range: $15.00-$15.22).
Key details of the transaction:
- The sale was automatically executed to cover estimated tax withholding obligations upon the vesting of restricted share units
- Transaction was made pursuant to automatic sale instructions in the Restricted Share Unit Agreement
- Following the transaction, Potts directly owns 115,073 ordinary shares
- The sale was non-discretionary and not a voluntary trade by the insider
This Form 4 filing was signed by Christian Klemt as Attorney-in-Fact on June 20, 2025, and demonstrates standard tax-related share disposition following equity compensation vesting.